Sale of Banned Medicines

I have sufficient grounded facts. Writing the note now.

Sale of Banned Medicines — UPSC Study Note

1. At a Glance

• Sale of Banned Medicines refers to enforcement against manufacture, sale and distribution of drugs prohibited by the Central Government under Section 26A of the Drugs and Cosmetics Act, 1940, primarily targeting irrational Fixed Dose Combinations (FDCs) [S1][S2].
• Regulated by CDSCO (Central Drugs Standard Control Organisation) under the Ministry of Health & Family Welfare; the Department of Pharmaceuticals sits under the Ministry of Chemicals and Fertilizers [S1].
• Examinable for GS-II (Health governance, statutory bodies) and GS-III (Pharma sector, consumer safety).

2. Why in the News

• PIB release dated 6 February 2026 by the Department of Pharmaceuticals tabled year-wise drug-ban data (2021–2025); flagged that High Court interim protections are blunting FDC bans [S1].

3. Background & Evolution

• Drugs and Cosmetics Act, 1940 — parent statute regulating import, manufacture, distribution and sale [S2].
• Section 26A inserted by amendment empowers Centre to prohibit a drug in public interest where risk exists or therapeutic justification is absent [S2].
• 10 March 2016 — Centre banned 344 FDCs by gazette notification; later expanded by 5 more [S2].
• 15 December 2017 — Supreme Court directed Drugs Technical Advisory Board (DTAB) to re-examine FDCs [S2].
• 7 September 2018 — Centre prohibited 328 FDCs on DTAB recommendation; 6 FDCs restricted with conditions [S2].
• Cumulatively, 603 drugs/FDCs for human use and 40 drugs for animal use had been prohibited as of the 2018 baseline [S2].

4. Core Static Facts

• Parent Act: Drugs and Cosmetics Act, 1940 [S2].
• Key provision: Section 26A (prohibition power); Section 27 (penalties) [S2][S3].
• Statutory expert body: Drugs Technical Advisory Board (DTAB) [S2].
• Regulator: CDSCO under MoHFW; Drugs Controller General of India (DCGI) is the apex authority [S2].
• Penalty for Section 26A contravention: Imprisonment up to 3 years and fine [S3].
• Spurious/adulterated drug causing death/grievous hurt: Imprisonment not less than 10 years, extendable to life; fine ≥ ₹10 lakh or 3× value of confiscated drugs [S3].
• Year-wise drugs banned (Centre) [S1]:
• 2021: NIL
• 2022: NIL
• 2023: 14 (human) + 2 (animal)
• 2024: 157 (human) + 1 (animal)
• 2025: 1 (human) + 36 (animal)

5. Multi-Dimensional Analysis

Legal / Constitutional - Centre's power under Section 26A has repeatedly been challenged in High Courts; petitioners secured interim protection for stock already in distribution channels, diluting enforcement [S1]. - Supreme Court's 2017 directive forced expert re-examination, embedding judicial oversight over executive drug bans [S2].

Administrative - Dual federal structure: Centre bans and licenses new drugs (CDSCO); States license manufacturers and inspect retail (State Drug Controllers) — creates enforcement gaps for banned stock at pharmacy level [S2]. - DTAB review is the procedural anchor before Section 26A notifications [S2].

Scientific / Public Health - FDC bans target combinations lacking therapeutic justification and posing risk (e.g., irrational antibiotic + analgesic mixes feeding antimicrobial resistance) [S2]. - Animal-use drug bans (36 in 2025) reflect One-Health concerns over zoonotic transmission and residue in food chain [S1].

Economic - India is the "pharmacy of the world" — bans hit a multi-thousand-crore FDC segment; industry litigation reflects revenue stakes [S2].

Ethical / Governance - Tension between pharma industry interests, public health precaution, and judicial caution on livelihoods/stock-in-trade.

6. Recent Developments (last 12–18 months)

• 2024: Largest single-year action — 157 human-use drugs banned [S1].
• 2025: Sharp pivot to veterinary use — 36 animal-use drugs banned vs only 1 for human use [S1].
• 6 Feb 2026: PIB statement reiterates that manufacture/sale/distribution of banned drugs is a punishable offence under the 1940 Act; High Court interim orders ongoing [S1].

7. Prelims Hooks

• Section 26A of the Drugs and Cosmetics Act, 1940 empowers the Central Government (not States) to ban drugs [S2].
• CDSCO is the central drug regulator; sits under Ministry of Health & Family Welfare, not Ministry of Chemicals [S1][S2].
• Department of Pharmaceuticals is under Ministry of Chemicals and Fertilizers [S1].
• DTAB is the statutory advisory body that recommended the 2018 FDC ban [S2].
• 328 FDCs banned via gazette notification dated 7 September 2018 [S2].
• Earlier 344 FDCs banned on 10 March 2016 [S2].
• Supreme Court order date: 15 December 2017 — directed DTAB re-examination [S2].
• In 2021 and 2022 — NIL drugs were banned by the Centre [S1].
• 2024: 157 human + 1 animal drug banned (peak year) [S1].
• Penalty for Section 26A breach: up to 3 years' imprisonment + fine [S3].
• Spurious drug causing death: minimum 10 years, extendable to life imprisonment; fine ≥ ₹10 lakh [S3].
• DCGI = Drugs Controller General of India, head of CDSCO [S2].

8. Mains Relevance

• GS-II: Issues relating to development and management of Social Sector — Health; Statutory bodies.
• GS-III: Indian economy — pharma sector; Issues of consumer protection.
• Question stems: 1. "Critically examine the effectiveness of Section 26A of the Drugs and Cosmetics Act, 1940 in curbing irrational Fixed Dose Combinations in India." 2. "Discuss the federal and judicial bottlenecks in enforcing bans on harmful medicines in India." 3. "Irrational FDCs contribute to antimicrobial resistance. Evaluate India's regulatory response."

9. Related Topics to Study Next

• Antimicrobial Resistance (AMR) & National Action Plan — public-health driver of FDC bans.
• Jan Aushadhi / PMBJP — generics policy under Dept. of Pharmaceuticals.
• National Pharmaceutical Pricing Authority (NPPA) — price regulation arm.
• DPCO 2013 & Essential Medicines List — adjacent regulatory regime.
• Mashelkar Committee (2003) — spurious drugs reform blueprint.
• Drugs and Cosmetics (Amendment) Bills / proposed New Drugs Bill — pending legislative overhaul.
• One Health approach — links animal-drug bans to human safety.
• Consumer Protection Act, 2019 — overlapping remedy.

10. Common Errors / Trap Areas

• Confusing Department of Pharmaceuticals (Chemicals & Fertilizers Ministry) with CDSCO (Health Ministry) [S1][S2].
• Citing Drugs and Cosmetics Act, 1945 — the Rules are 1945; the Act is 1940 [S2].
• Section 26A is sometimes wrongly attributed to State governments — it is a Central power [S2].
• Assuming bans are immediately effective — High Court interim orders routinely shield existing distribution stock [S1].
• Mixing up DTAB (technical advisory) with DCC (Drugs Consultative Committee) — DTAB recommends bans [S2].

11. Sources

• [S1] Sale of Banned Medicines — PIB, Department of Pharmaceuticals, 06 Feb 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224370 — (tier 1)
• [S2] Prohibition and restriction of manufacture, sale and distribution of FDCs — PIB — https://www.pib.gov.in/Pressreleaseshare.aspx?PRID=1545741 — (tier 1)
• [S3] The Drugs and Cosmetics Act, 1940 (bare act) — India Code — https://www.indiacode.nic.in/bitstream/123456789/15278/1/drug_cosmeticsa1940-23.pdf — (tier 1)